DPYD
Universal Cellular Machinery · Core Enzymatic Catalysis & Cofactor Chemistry
Why might DPYD be checked before certain cancer medicines?
DPYD makes an enzyme that breaks down pyrimidine compounds and participates in fluoropyrimidine drug metabolism. Reduced activity can matter for treatment toxicity, so any prescribing use requires a clinically interpreted result for the planned drug.
- Common Gene Name
- dihydropyrimidine dehydrogenase
- NCBI Gene ID
- 1806
- Chromosome
- 1
Clinical Evidence Status
Drug-response evidence availableTumor or drug-label biomarker context
These labels describe available evidence about a gene. They do not classify your variant or recommend a treatment.
Answer Sources
Explore supporting evidence (7 records)
| Condition or drug | Evidence | Grade / status | Context | Source |
|---|---|---|---|---|
| Coloboma | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2011-11 | |
| Dihydropyrimidine dehydrogenase deficiency | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2011-11 | |
| Capecitabine | FDA pharmacogenetics | Management recommendation | Drug-specific subgroup | View source |
| Fluorouracil | FDA pharmacogenetics | Management recommendation | Drug-specific subgroup | View source |
| Capecitabine (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Fluorouracil (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Dermatology | View source |
| Fluorouracil (2) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
Source snapshot: 2026-09-09. Consumer text updated: 2026-09-10. Source dates describe the cited records, not a new clinical review.
← Back to Universal Cellular Machinery